Document is current

Article History

Received: 29 October 2024

Accepted: 17 January 2025

First Online: 20 February 2025

Declarations

:

: Financial arrangements of the authors with companies whose products may be related to the present manuscript are listed, as declared by the authors. Angela Crowley: Speaker fees from AbbVie, GSK, Horizon, and Janssen; consulting fees from AstraZeneca, Novartis, and UCB; and research funding from AbbVie, Lilly, Labcorp, SetPoint Medical, and Sun Pharma. Lori Siegel: Speaker and consulting fees from AbbVie, Amgen, Boehringer Ingelheim, GSK, Novartis, UCB, and Sanofi-Genzyme. Rebecca Grainger: Speaker fees from AbbVie, Pfizer, Cornerstone, and Janssen; consultant for AbbVie and Novartis. Philip J. Mease: Speaker fees from AbbVie, Amgen, Lilly, Janssen, Novartis, Pfizer, and UCB; consultant for AbbVie, Acelyrin, Amgen, BMS, CorEvitas, Cullinan, Lilly, Inmagene, Janssen, MoonLake, Novartis, Pfizer, and UCB; grant/research support from AbbVie, Acelyrin, Amgen, BMS, Lilly Janssen, Novartis, Pfizer, and UCB. Jeffrey R. Curtis: Consulting fees and research support from AbbVie, Amgen, Bristol Myers Squibb, Janssen, CorEvitas, Lilly, Novartis, Sanofi, Pfizer, and UCB. Dan E. Webster, Tiancheng He, Liuqing Yang, Elina Moon, Dee-Dee Shiller, Michelle Crouthamel, and Heather Jones: Employees of AbbVie and may hold stock or options.

: Studies were conducted per the International Conference on Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. Study-related documents were reviewed and approved by the Advarra Institutional Review Board (OHRP/FDA-registered IRB#00000971). All participants provided written, informed consent.